FDA Clears Cancer Drug Keyed to Genetics - Diverse Health

Higher Education News and Jobs

FDA Clears Cancer Drug Keyed to Genetics

Email
   
        


by Natalie Grover and Bill Berkrot

Merck & Co’s immunotherapy Keytruda chalked up another approval on Tuesday as the U.S. Food and Drug Administration said the cancer medicine can be used to treat children and adults who carry a specific genetic feature regardless of where the disease originated.

It is the first time the agency has approved a cancer treatment based solely on a genetic biomarker.

“Until now, the FDA has approved cancer treatments based on where in the body the cancer started – for example, lung or breast cancers,” said Richard Pazdur, head of oncology products for the FDA’s Center for Drug Evaluation and Research.

Read More

Comments

Print Friendly

Related Articles

Senate Starts New Round on Repeal Votes Senate Republicans forged ahead Wednesday with proposals aimed at revamping the Affordable Care Act, hoping to produce some sort of legislation that could garner enough support to serve as the basis of negotiations with the House. But after they w...
Trump Thinks Health Insurance Costs Young $12 a Year President Donald Trump has an...interesting conception of how health insurance works. In a new interview with the New York Times, Trump defended his knowledge of health care and the Senate's chaotic attempts to pass a Republican health care bill t...
Suburban Living Reduces Dementia Risks Living in the suburbs could help protect you from dementia, a study found. People in poorer areas were far more likely to show the early signs of Alzheimer’s disease than those who lived in wealthier districts. Scientists believe factors such a...
3 Ways Repeal Would Devastate Communities of Color Last August, then-candidate Donald Trump tried to court voters of color by asking, “What the hell do you have to lose?” When it comes to health care, the answer is clear: everything. Senate Republicans are poised to vote for the Better Care Reconcili...